← All trials
NCT04475081
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2020
- Primary completion
- Oct 31, 2021
- Completion date
- Dec 1, 2021
- First posted
- Jul 17, 2020
- Last posted
- Jul 20, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Louisiana State UniversityLead sponsor
- Louisiana State UniversityReponsible party - principal investigator
- Louisiana State UniversityOverall official - principal investigator
- Parsemus FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.